Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
18/26/18	0.6110 €	0.00%
17/26/17	0.6110 €	0.00%
16/26/16	0.6110 €	0.00%
15/26/15	0.6110 €	0.00%
12/26/12	0.6110 €	0.00%

Real-time Euronext Bruxelles

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.6110EUR

Average target price

1.500EUR

Spread / Average Target

+145.50%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Bruxelles Other stock markets 09:25:00 18/06/2026 pm IST			5-day change	1st Jan Change
0.6110 ^EUR	0.00%		0.00%	-3.63%

29/05	Sequana Medical Presents Data on Recompensation of Decompensated Cirrhosis Following Alfapump Placement At EASL Congress 2026	CI
24/12	Sequana Medical Agrees Loan Amendment with Kreos Capital	MT

Market Cap	4.36Cr 5Cr 4.02Cr 3.78Cr 7.07Cr 471.15Cr 7.12Cr 48Cr 19Cr 232.19Cr 19Cr 18Cr 804.77Cr	P/E 2025 *	-3.59x	P/E 2026 *	-3.39x
Enterprise Value	3.09Cr 3.54Cr 2.84Cr 2.68Cr 5.01Cr 333.78Cr 5.04Cr 34Cr 13Cr 164.49Cr 13Cr 13Cr 570.13Cr	EV / Sales 2025 *	44.1x	EV / Sales 2026 *	8.63x
Free-Float	75.76%	Yield 2025 *	-	Yield 2026 *	-

29/05	Sequana Medical Presents Data on Recompensation of Decompensated Cirrhosis Following Alfapump Placement At EASL Congress 2026	CI
24/12	Sequana Medical Agrees Loan Amendment with Kreos Capital	MT
23/12	Sequana Medical Announces Execution of Letter of Intent to Amend Terms of the Kreos Loan	CI
11/12	Sequana Medical Announces U.S. Commercial Alfapump®? Implantations at University of Pennsylvania	CI
26/25/26	Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2025	CI
16/25/16	Sequana Medical Issues Subscription Request Notice to GEM Global Yield	MT
16/25/16	Sequana Medical NV announced that it expects to receive funding from Global Emerging Markets	CI
08/25/08	Sequana Medical Issues Subscription Request Notice with Investor	MT
06/25/06	US Government Agency Approves Add-on Payment for Sequana Medical's Alfapump System	MT
31/25/31	Sequana Medical Nv Announces the Publication of Use of Alfapump to Control Ascites Enabling Elective Abilical Hernias Enabling Elective Umbilical Hernia Repair Published in Hernia	CI
27/25/27	Sequana Medical Obtains Additional EUR6.3 Million Convertible Loan from Shareholders	MT
27/25/27	Sequana Medical NV announced that it has received ?30.3 million in funding from Global Emerging Markets, EQT Life Sciences, Partners In Equity V B.V.	CI
23/25/23	Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2024	CI

29/04	Sequana Medical N : Convening Notice (Convening Notice ENG 28 April 2026)	PU
29/04	Sequana Medical N : Auditor report of default on the consolidated accounts for the year ended 31 December 2025 (Auditor Report of default 2025 conso ENG 28 April 2026)	PU
29/04	Sequana Medical N : Auditor report of default on the accounts for the year ended 31 December 2025 (Auditor Report of default 2025 ENG 28 April 2026)	PU
29/04	Report of the board of directors in accordance with article 7:228 of the Belgian Companies and Associations Code (Board Report 7 228 Financial Alarm Bell ENG 28 April 2026)	PU
08/12	SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES	AQ

Sequana Medical N.V. Share Price

Stocks

SEQUA

BE0974340722

Biotechnology & Medical Research

Valuation: Sequana Medical N.V.

Chart: Sequana Medical N.V.

Latest news : Sequana Medical N.V.

Press Releases: Sequana Medical N.V.

News in other languages: Sequana Medical N.V.

Quotes and Performance

Course Extremes

Managers and Directors: Sequana Medical N.V.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

29/05	Sequana Medical presenteert nieuwe studieresultaten
29/05	Sequana Medical N : kondigt presentatie aan over recompensatie van gedecompenseerde cirrose na plaatsing van alfapump® tijdens EASL Congres 2026
03/05	Aperam beloond voor cijfers
29/04	Sequana Medical N : Outstanding Shares and Voting Rights NL/EN (Overview of Outstanding Shares and Voting Rights NL ENG 28 April 2026)
29/04	Sequana Medical N : Verslag van de commissaris van niet-bevinding over de geconsolideerde jaarrekening voor het boekjaar afgesloten op 31 december 2025 (Commissarisverslag niet bevinding FY 2025 conso NL 28 April 2026)

1 week	0.61	0.61
1 month	0.61	0.61
Current year	0.46	0.68
1 year	0.46	1.62
3 years	0.46	4.85
5 years	0.46	9.6
10 years	0.46	12.4

Manager	Title	Age	Since
Ian Crosbie CEO	Chief Executive Officer	58	01/01/2016
Kirsten van Bockstaele DFI	Director of Finance/CFO	52	01/07/2018
Andreas Wirth CTO	Chief Tech/Sci/R&D Officer	58	01/01/2021

Director	Title	Age	Since
Douglas Kohrs BRD	Director/Board Member	68	19/07/2022
Wim Ottevaere BRD	Director/Board Member	70	08/11/2018
Ids van der Weij BRD	Director/Board Member	-	10/11/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
07/23/07	Pierre Hubert Andre Chauvineau	Fiscal year	Chairman	12,755	0.0452%
07/23/07	Douglas Kohrs	Fiscal year	Director	12,755	0.0452%
07/23/07	Alexandra Clyde	Sell	Director	12,755	0.0452%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEQUANA MEDICAL N.V.	0.00%	0.00%	-41.14%	-80.79%	5.05Cr
LONZA GROUP AG	-0.34%	-0.08%	-12.15%	-10.46%	4.34TCr
REVOLUTION MEDICINES, INC.	+1.45%	+7.43%	+301.50%	+524.30%	3.35TCr
IQVIA HOLDINGS INC.	-3.00%	-9.61%	+5.85%	-23.85%	2.85TCr
BEONE MEDICINES AG	+2.60%	+2.39%	+5.42%	+39.11%	2.92TCr
CELLTRION, INC.	-0.57%	+3.77%	+12.66%	+20.42%	2.53TCr
ASCENDIS PHARMA A/S	+0.36%	+8.12%	-	-	1.44TCr
MEDPACE HOLDINGS, INC.	+0.14%	-4.27%	+50.24%	+101.86%	1.31TCr
EUROFINS SCIENTIFIC SE	+0.54%	-2.27%	+3.93%	+4.80%	1.27TCr
IONIS PHARMACEUTICALS, INC.	+0.11%	+0.53%	+100.51%	+80.69%	1.23TCr
Average	+0.12%	+0.72%	+47.43%	+72.90%	2.12TCr
Weighted average by Cap.	+0.11%	+0.79%	+61.44%	+103.45%

	2025 *	2026 *
Net sales	7L 8L 6L 6L 11.35L 7.57Cr 11.43L 76.77L 29.81L 3.73Cr 30.16L 29.51L 13Cr	63L 72.31L 58.08L 54.63L 1.02Cr 68Cr 1.03Cr 6.91Cr 2.68Cr 34Cr 2.71Cr 2.66Cr 116.4Cr
Net income	-3.04Cr -3.49Cr -2.8Cr -2.64Cr -4.93Cr -328.83Cr -4.97Cr -33Cr -13Cr -162.05Cr -13Cr -13Cr -561.67Cr	-3.24Cr -3.71Cr -2.98Cr -2.8Cr -5.25Cr -349.92Cr -5.28Cr -35Cr -14Cr -172.44Cr -14Cr -14Cr -597.7Cr
Net Debt	-1.27Cr -1.46Cr -1.17Cr -1.1Cr -2.06Cr -137.37Cr -2.07Cr -14Cr -5.41Cr -68Cr -5.47Cr -5.35Cr -234.64Cr	1.08Cr 1.24Cr 99.56L 93.64L 1.75Cr 116.82Cr 1.76Cr 12Cr 4.6Cr 58Cr 4.65Cr 4.55Cr 199.54Cr

3 months	+20.99%
6 months	-19.61%
Current year	-3.63%